- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.07. | Kairos Pharma Announces Strategic Collaboration With Bayer To Enhance XOFIGO Activity In Metastatic Prostate Cancer | 34 | pulse2.com | ||
| 22.07. | Bayer, Kairos Pharma Collaborate to Boost Xofigo Effectiveness in Metastatic Prostate Cancer | 47 | Contract Pharma | ||
| KAIROS PHARMA Aktie jetzt für 0€ handeln | |||||
| 22.07. | Kairos Pharma partners with Bayer on prostate cancer study | 53 | Investing.com | ||
| 22.07. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.07. | Kairos Pharma (KAPA) Stock Surges Over 22% After Hours: Why is it Moving? | 1 | Benzinga.com | ||
| 15.07. | CEO.CA Technologies Ltd.: CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever | 389 | Newsfile | Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining... ► Artikel lesen | |
| 15.07. | Kairos Pharma, LTD. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.06. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.06. | Kairos Pharma signs term sheet to acquire lung cancer asset | 3 | Investing.com | ||
| 04.06. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.05. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Kairos Pharma, LTD. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | LD Micro: Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI | 540 | Newsfile | Los Angeles, California--(Newsfile Corp. - May 13, 2026) - Kairos Pharma, Ltd. (NYSE American: KAPA) announced today that it will be participating in the 16th Annual LD Micro Invitational at the... ► Artikel lesen | |
| 08.05. | Kairos Pharma: Interview With Chairman & CEO Dr. John Yu About The Biopharmaceutical Company | 1 | pulse2.com | ||
| 31.03. | Kairos Pharma, LTD. - 10-K, Annual Report | 1 | SEC Filings | ||
| 03.03. | Kairos Pharma signs deal for Celyn Therapeutics' CL-273 | 1 | Pharmaceutical Technology | ||
| 02.03. | Kairos Pharma signs deal to acquire lung cancer drug CL-273 | 1 | Investing.com | ||
| 26.02. | Kairos Pharma, Ltd. gibt Unterzeichnung einer Grundsatzvereinbarung über den strategischen Erwerb von zwei klinischen Onkologie-Assets von Celyn Therapeutics bekannt | 420 | Business Wire | Durch diese transformative Transaktion im Bereich der klinischen Pipeline werden CL-273, ein Pan-EGFR-Inhibitor, und CL-741, ein Phase-1-fähiger c-MET-Inhibitor, in das klinische Portfolio von Kairos... ► Artikel lesen | |
| 26.02. | Kairos Pharma signs term sheet to acquire lung cancer assets | 2 | Investing.com | ||
| 26.02. | Kairos Pharma, LTD. - 8-K, Current Report | 2 | SEC Filings |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 0,580 | +1,05 % | Inovio Pharmaceuticals, Inc.: INOVIO Announces Pricing of $20.0 Million Public Offering | PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing... ► Artikel lesen | |
| INFLARX | 1,585 | -0,69 % | InflaRx N.V.: InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones | Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as plannedInitiated feasibility assessment for broadened strategy for... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,300 | -0,39 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S.... ► Artikel lesen | |
| IBIO | 1,264 | +3,27 % | iBio, Inc.: iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer | SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| IMMUNITYBIO | 6,550 | -0,76 % | IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake | ||
| IMMATICS | 8,280 | +2,92 % | Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 | Houston, Texas and Tuebingen, Germany, July 17, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MANNKIND | 3,540 | 0,00 % | H.C. Wainwright reiterates Buy rating on MannKind stock at $10 | ||
| IMMUNIC | 13,180 | +6,59 % | EQS-News: Immunic AG: Immunic to Participate in Investor Conferences in July | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor Conferences in July
09.07.2026 / 12:30 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 5,500 | +0,36 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates | U.S. Amtagvi Revenue Reaches ~$91M and Total Revenue Increased 66% Year-over-Year Gross Margin Increased to 56% Fast Track Designation (FTD) Granted by the FDA for Lifileucel in Soft Tissue Sarcomas... ► Artikel lesen | |
| MOLECULIN BIOTECH | 0,409 | -0,10 % | Moleculin Biotech, Inc.: Moleculin Announces Pricing of $9.3 Million Public Offering | HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced the pricing of a best-efforts public offering of an aggregate of... ► Artikel lesen | |
| GENPREX | 4,300 | +0,70 % | Genprex, Inc.: Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies | Collaboration Advances Biomarker-Driven Patient Selection and Precision Medicine in Oncology
Validation Studies Aim to Optimize Clinical Trial Patient Selection... ► Artikel lesen | |
| MESOBLAST | 1,380 | +1,36 % | Mesoblasts führende Zelltherapie erzielt im ersten vollständigen Verkaufsjahr einen Umsatz von 115 Mio. US-Dollar | ||
| MACROGENICS | 3,360 | -4,00 % | MacroGenics, Inc.: MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026 | Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enrolling... ► Artikel lesen | |
| KARYOPHARM | 1,740 | -4,40 % | Karyopharm Therapeutics Inc.: Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer | - The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival (PFS) -
- A Trend Favoring the Selinexor Arm was Observed with a 5.3 Month Improvement... ► Artikel lesen | |
| MEREO BIOPHARMA | 0,254 | -1,55 % | Mereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates | LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial... ► Artikel lesen |
Das Unternehmen KAIROS PHARMA LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,385 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KAIROS PHARMA LTD finden Sie auf Wallstreet Online.